Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epacadostat + nivolumab + lirilumab
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (epacadostat), Intravenous (nivolumab), Intravenous (lirilumab)
01
Overview
A **combination of three immunotherapy drugs**: epacadostat, a selective inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1); nivolumab, a monoclonal antibody against programmed death-1 (PD-1); and lirilumab, a monoclonal antibody directed at the killer cell immunoglobulin-like receptor (KIR). This combination was investigational for advanced or metastatic solid tumors, aiming to improve anti-tumor immune response by simultaneously blocking pathways that suppress T-cell and NK-cell function. Epacadostat was developed by **Incyte**, nivolumab and lirilumab by **Bristol Myers Squibb**. The regimen sought to determine safety, tolerability, and efficacy in several cancer types, including melanoma, non-small cell lung cancer, and squamous cell carcinoma of the head and neck[2][1].
- Brand names
- Opdivo (nivolumab)None for epacadostat or lirilumab as of current data
- Other names
- epacadostat + nivolumab + lirilumab
02
Targets
iKIR (Inhibitory killer-cell immunoglobulin-like receptors)IDO1 (Indoleamine 2,3-dioxygenase 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on epacadostat + nivolumab + lirilumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epacadostat + nivolumab + lirilumab.